Inhaled Corticosteroids Particle Size and Risk of Hospitalization Due to Exacerbations and All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease. A Nationwide Cohort Study
Christian Kjer Heerfordt,Christian Rønn,Josefin Eklöf,Pradeesh Sivapalan,Zitta Harboe,Charlotte Hyldgaard,Andreas Fløe,Alexander Mathioudakis,Mats Lassen,Tor Biering-Sørensen,Jens-Ulrik Jensen
DOI: https://doi.org/10.2147/copd.s453524
2024-09-29
International Journal of COPD
Abstract:Christian Kjer Heerfordt, 1 Christian Rønn, 1 Josefin Eklöf, 1 Pradeesh Sivapalan, 1 Zitta Barrella Harboe, 2, 3 Charlotte Hyldgaard, 4 Andreas Fløe, 5 Alexander G Mathioudakis, 6, 7 Mats Christian Højbjerg Lassen, 8 Tor Biering-Sørensen, 8, 9 Jens-Ulrik Stæhr Jensen 1, 3, 10 1 Section of Respiratory Medicine, Department of Medicine, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark; 2 Department of Respiratory Medicine and Infectious Diseases, Copenhagen University Hospital, North Zealand, Hillerød, Denmark; 3 Department of Clinical Medicine Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 4 Diagnostic Centre, University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark; 5 Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark; 6 Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK; 7 North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; 8 Department of Cardiology, Herlev & Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark; 9 Faculty of Biomedical Sciences, Copenhagen University, Copenhagen, Denmark; 10 PERSIMUNE & CHIP: Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark Correspondence: Jens-Ulrik Stæhr Jensen, Email Background: Extra-fine particle inhaled corticosteroids (ICS) improve peripheral airway distribution, but their effect on risk of exacerbations and all-cause mortality in patients with chronic obstructive pulmonary disease (COPD) is unclear. Methods: This observational cohort study compares patients with COPD who received extra-fine particle ICS to those who received standard particle size ICS from 2010 to 2017 while followed in outpatient clinics. The primary outcome was the time to a COPD exacerbation that required hospitalization, with all-cause mortality as a secondary outcome. Data were analyzed using an adjusted Cox proportional hazards model and a competing risk analysis. Two predefined subgroup analyses of patients treated with pressurised metered dose inhalers (pMDIs) and patients with a previous exacerbation history, was carried out. Lastly, we created a propensity score matched cohort as a sensitivity analysis. Results: Of the 40,489 patients included, 38,802 (95.8%) received stand particle size ICS and 1,687 (4.2%) received extra-fine particle ICS. In total 7,058 were hospitalized with a COPD exacerbation, and 4,346 died. No significant protective effect of extra-fine particle ICS against hospitalization due to COPD exacerbations (HR 0.93, 95% CI 0.82– 1.05, p=0.23) or all-cause mortality (HR 1.00, 95% CI 0.85– 1.17, p=0.99) was found when compared to standard particle size ICS. However, in the subgroup analysis of patients treated with pMDIs, extra-fine particle ICS was associated with reduction in risk of exacerbations (HR 0.72, 95% CI 0.63– 0.82, p< 0.001) and all-cause mortality (HR 0.72, 95% CI 0.61– 0.86, p< 0.001). Conclusion: The administration of extra-fine particle ICS was not associated with reduced risk of exacerbations or all-cause mortality in our primary analysis. A subgroup consisting of patients treated with pMDIs suggested potential protective benefits. Keywords: COPD, Inhaled Corticosteroids, Particle size, COPD exacerbations Inhaled corticosteroids (ICS) are commonly used for treatment of Chronic Obstructive Pulmonary Disease (COPD) in combination with bronchodilators. 1,2 ICS therapy has been shown to effectively prevent exacerbations in COPD patients with a history of frequent exacerbations and evidence of eosinophilic inflammation. 3–5 The impact of ICS on mortality in these patients is still somewhat uncertain. 2,6 The ETHOS and IMPACT trials suggest beneficial effects on all-cause mortality, although in milder COPD populations compared to our cohort. 7,8 ICS particle size affects the distribution within the lungs. 9,10 The median mass aerodynamic diameter (MMAD) is the measure of particle size for ICS, which typically ranges from 1–5 μm in commonly used devices. 11 Extra-fine ICS particles, with a MMAD of less than 2 μm, are more likely to reach the peripheral airways. 9,12 The increased distribution of ICS in the peripheral airways may potentiall -Abstract Truncated-
respiratory system